Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ironwood Pharmaceuticals Inc Market Cap
The Ironwood Pharmaceuticals Inc (IRWD) share price is expected to increase by 255.11% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered IRWD. Price targets range from $5 at the low end to $23 at the high end. The current analyst consensus for IRWD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedIRWD 5 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Ironwood Pharmaceuticals Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IRWD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IRWD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Faisal Khurshid Leerink Partners | Market Perform | $5 | Initiates | Sep 9, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $10 | Maintains | Aug 9, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $12 | Maintains | Aug 9, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $14 | Maintains | May 10, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $14 | Maintains | Mar 1, 2024 |
| David Amsellem Piper Sandler | Overweight | $21 | Maintains | Feb 16, 2024 |
| Chase Knickerbocker Craig-Hallum | Buy | $21 | Initiates | Jan 17, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $20 | Initiates | Dec 14, 2023 |
| Jason Butler JMP Securities | Market Outperform | $22 | Initiates | Sep 28, 2023 |
| David Amsellem Piper Sandler | Overweight | $19 | Maintains | May 23, 2023 |
Piper Sandler | Overweight | Initiates | Aug 29, 2022 | |
| Jacob Hughes Wells Fargo | Equal-Weight | $13 | Maintains | Aug 16, 2022 |
Piper Sandler | Overweight | Initiates | Apr 22, 2022 | |
| David Lebowitz Morgan Stanley | Equal-Weight | $14 | Maintains | Oct 12, 2021 |
| David Lebowitz Morgan Stanley | Equal-Weight | $12 | Maintains | Jul 16, 2021 |
| David Lebovitz Morgan Stanley | Equal-Weight | $11 | Maintains | Feb 22, 2021 |
| David Lebovitz Morgan Stanley | Equal-Weight | $11 | Maintains | Feb 19, 2021 |
Morgan Stanley | Equal-Weight | $12 | Maintains | Nov 6, 2020 |
Credit Suisse | Neutral | $12 | Maintains | Nov 6, 2020 |
Wells Fargo | Equal-Weight | Downgrade | Sep 30, 2020 |
When did it IPO
2010
Staff Count
267
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Thomas A. McCourt
Market Cap
$563.3M
In 2023, IRWD generated $442.7M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IRWD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ironwood Pharmaceuticals will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 4, 2024, at 12:30 p.m. ET. The event will be webcast live on their website.
Why It Matters - Ironwood Pharmaceuticals' participation in a prominent healthcare conference signals potential insights into their strategies and performance, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ironwood Pharmaceuticals' COO and CFO, Sravan Emany, will speak at the Jefferies London Healthcare Conference on November 20, 2024. A live webcast will be available on their website.
Why It Matters - Ironwood Pharmaceuticals' CFO's participation in a key healthcare conference may signal potential strategic insights or updates, influencing investor sentiment and stock performance.
Fri, 08 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - IRWD's Q3 earnings fell short of estimates, but revenues exceeded expectations. The company has upheld its revenue guidance for 2024.
Why It Matters - Earnings miss may signal operational challenges, impacting investor confidence, while revenue beat and maintained guidance suggest growth potential, balancing short-term concerns with long-term outlook.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Ironwood Pharmaceuticals held its Q3 2024 earnings call on November 7, 2024, featuring executives from the company and analysts from various financial institutions.
Why It Matters - The earnings call provides insights into Ironwood Pharmaceuticals' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ironwood Pharmaceuticals reported third quarter 2024 results, highlighting a 13% year-over-year growth in LINZESS prescriptions, indicating strong demand in the GI-focused healthcare sector.
Why It Matters - Ironwood's strong LINZESS prescription growth signals robust demand, potentially boosting revenue and investor confidence in the company's future performance.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Ironwood Pharmaceuticals (IRWD) reported Q3 earnings of $0.02 per share, missing estimates of $0.09. This is a decline from $0.12 per share in the same quarter last year.
Why It Matters - Ironwood's earnings miss signals potential operational challenges and reduced profitability, which may lead to negative market sentiment and affect stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
